CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 7254 result(s)

2021 CADTH Virtual Symposium

Event Date: November 2, 2021 - November 4, 2021
Result type: Events

The 2021 CADTH Symposium will be held online on November 2, 3, and 4. The theme is Uncertain Times, Imperfect Evidence, and the Imperative to Act.  Take this opportunity to connect with Canadian and international experts for three days of education, information sharing, and networking on the objective assessment and evaluation of heal...

CADTH In Conversation With…. Professor Gillian Leng CBE, Chief Executive of NICE

Event Date: May 27, 2021
Result type: Events

Join Suzanne McGurn, President and CEO of CADTH, as she welcomes Gillian Leng, CBE, for an insightful conversation on what the future holds for the United Kingdom’s influential National Institute for Health and Care Excellence, better known as NICE. REGISTER NOW Gillian will discuss NICE’s new 5-year strategic plan and how it will impact the a...

semaglutide (Ozempic)

Last Updated: June 18, 2019
Result type: Reports
Product Line: Reimbursement Review
Generic Name: semaglutide
Indications: Diabetes mellitus, type 2

  • Brand Name: Ozempic
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0594-000
  • Project Status: Complete
  • Submission Type: Initial

patiromer (Veltassa)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: patiromer
Indications: For the treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m).

  • Brand Name: Veltassa
  • Manufacturer: Otsuka Canada Pharmaceuticals Inc.
  • Project Number: SR0665-000
  • Project Status: Active
  • Submission Type: Initial

semaglutide (Rybelsus)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: semaglutide
Indications: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes

  • Brand Name: Rybelsus
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0637-000
  • Project Status: Active
  • Submission Type: Initial

dupilumab (Dupixent)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dupilumab
Indications: Dupixent is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0667-000
  • Project Status: Active
  • Submission Type: Initial

risdiplam (Evrysdi)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: risdiplam
Indications: ​For the treatment of spinal muscular atrophy (SMA) in patients 2 months and older.

  • Brand Name: Evrysdi
  • Manufacturer: Hoffmann La-Roche Ltd.
  • Project Number: SR0661-000
  • Project Status: Active
  • Submission Type: Initial